The Peptide Question

Last week, Robert F Kennedy Jr went on the Joe Rogan Podcast and announced that the government is preparing to loosen restrictions on a group of experimental peptides the FDA restricted just a few years ago.

If you’re not familiar with peptides, I envy your blissful ignorance. I’m sick of talking about them. And RFK’s comments probably sounded to you like another obscure pharmaceutical policy change that only scientists and bureaucrats care about.

But not to me. The more I thought about it, the stranger it became.

Because it raised a simple question I couldn’t answer:

Why would the U.S. government want to do this?

Especially this government.

RFK has spent years warning Americans that the pharmaceutical industry pushes drugs onto the public without sufficient evidence of safety. He has questioned vaccines and even raised concerns about medications as commonplace as acetaminophen during pregnancy.

You don’t have to agree with those views to recognize the underlying principle.

The argument has always been the same:

Americans deserve stronger evidence before drugs reach the public.

Which is why his Rogan announcement caught my attention.

Because even RFK himself admitted on the podcast that the evidence supporting many of these peptides “hasn’t really been gathered yet.”

In other words, the same official who built his reputation warning about drugs with insufficient evidence is now proposing to expand access to compounds that, in many cases, have almost no clinical evidence at all.

So I did what pharmacists do when something in healthcare doesn’t make sense.

I tried to follow the logic.

This isn’t meant to be a peptide explainer, but I do want to make sure we are all on the same page.

Peptides are short chains of amino acids, the building blocks of proteins.

Some peptides are legitimate medicines. Insulin is a peptide. GLP-1 drugs like semaglutide (the active ingredient in Ozempic and Wegovy) are peptides.

But when people in the wellness world talk about peptides, they’re usually referring to a completely different category of compounds.

Things like:

These substances are often marketed as treatments for everything from muscle growth and fat loss to tissue repair and longevity.

The problem is that the evidence supporting many of these claims is thin at best.

Researchers studying these compounds say that most of the data comes from animal studies, small experimental trials, or anecdotal reports online — not rigorous human clinical trials.

In many cases, we still don’t know:

And yet they’ve already become wildly popular.

Peptides are now promoted by wellness influencers, biohacking clinics, and longevity enthusiasts across social media. Many are sold online as “research chemicals,” with disclaimers that they are not intended for human consumption — even though it’s obvious many buyers are injecting them themselves.

And that brings us back to RFK’s announcement.

Because the FDA restricted compounding of many of these peptides in 2023 due to safety concerns and lack of evidence.

Now the government appears poised to reverse that decision.

Which brings us back to the question.

Why?

The first explanation RFK offered is fairly straightforward.

If the FDA continues to ban peptides, he says people will simply buy them from the black market anyway (as they are doing now).

Legalizing compounding, the argument goes, could push consumers toward “ethical suppliers” instead of sketchy online labs.

On the surface, that sounds reasonable.

But it raises an obvious question.

If the solution to dangerous black markets is legalization, why does that logic apply to peptides but not to other drugs people clearly obtain on the black market anyway?

Americans buy heroin, cocaine, and counterfeit pills every day despite prohibition.

Those markets are notoriously contaminated with fentanyl and other dangerous adulterants.

Yet no one in Washington is proposing that we legalize those substances so people can purchase them from “ethical suppliers.”

If the goal of drug policy is harm reduction, it’s worth asking why that philosophy suddenly appears for experimental peptides — but nowhere else.

Either the logic applies broadly, or it doesn’t.

And right now, it doesn’t.

The second explanation may be less philosophical and more practical.

Peptides have become one of the fastest-growing corners of the wellness industry.

In the past few years they’ve moved from niche biohacking forums into the mainstream:

In some cities, peptide shots are now offered alongside IV vitamin drips and hormone therapy.

In other words, peptides aren’t just a scientific topic anymore.

They’re an industry.

And it’s an industry with a large, enthusiastic customer base.

That raises another possibility.

This may simply be good politics.

There is enormous enthusiasm for peptides in many of the same online communities that helped fuel the Make America Healthy Again movement.

Legalizing them would instantly create a regulatory victory that resonates with millions of voters who believe the FDA has been suppressing alternative medicine.

Whether intentional or not, the move would send a clear message to that constituency:

Washington is on your side.

In an election year, that kind of policy shift does more than change drug regulation.

It builds political loyalty.

There’s another possibility that occurred to me.

And this one sits squarely in the world I know best: compounding.

For the past two years, compounding pharmacies have been making enormous amounts of money producing versions of GLP-1 drugs like semaglutide and tirzepatide.

I’ve written extensively about this.

But as I wrote about three weeks ago, those days may be coming to an end.

Regulators are already signaling a crackdown on compounded GLP-1s as brand-name supply stabilizes and pharmaceutical companies push to defend their patents.

If that crackdown happens, thousands of compounding pharmacies will suddenly lose their most profitable product line.

Opening the peptide market could provide something else to sell.

Unlike GLP-1s, most experimental peptides don’t threaten major pharmaceutical patents.

There are no blockbuster drugs at stake.

Which makes peptides politically easier to liberalize.

In that scenario, the policy could function as a kind of tradeoff:

Maybe this is the government throwing Hims a bone so they ease off their GLP-1 litigation.

I don’t know if that’s the intention here.

But the incentives line up.

The final explanation is the simplest.

RFK has repeatedly framed this issue as part of a broader campaign to end what he calls the FDA’s “war on alternative medicine.”

From that perspective, the argument is philosophical.

Americans should have more freedom to experiment with their own health.

If people want to try experimental compounds in pursuit of longevity, muscle growth, or disease prevention, the government shouldn’t stand in the way.

It’s essentially a libertarian approach to medicine.

But again, the inconsistency is hard to ignore.

That philosophy appears very comfortable expanding access to experimental peptides.

It appears far less comfortable when applied to other parts of modern medicine.

Maybe one of these explanations is correct.

Maybe several of them are.

But from where I sit as a pharmacist, the bigger issue is consistency.

At the same time regulators are threatening legal action against companies selling compounded versions of FDA-approved GLP-1 drugs, the government appears ready to expand access to experimental peptides that have never been approved at all.

That’s a strange set of priorities for a health system that claims to be evidence-based.

Because the fundamental principle of medicine is supposed to be straightforward:

Evidence comes first.

Drugs become widely available only after clinical trials demonstrate safety and effectiveness.

If peptides eventually prove safe and effective, they will earn their place in medicine the same way every other drug does.

Through data.

Through trials.

Through scrutiny.

Skipping that process doesn’t make science move faster.

It just turns the public into the experiment.

And that’s a policy decision worth understanding before the experiment begins — because once the cat’s out of the bag, we all become the lab rats.

Alec Wade Ginsberg, PharmD, RPh
4th-Gen Pharmacist | Owner & COO, C.O. Bigelow
Founder, Drugstore Cowboy